Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures.
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
B-Lymphocytes
/ immunology
COVID-19
/ immunology
Female
High-Throughput Nucleotide Sequencing
Humans
Lymphopenia
/ immunology
Male
Middle Aged
Receptors, Antigen, B-Cell
/ genetics
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
B-cell repertoire
BCR
COVID-19
SARS-CoV-2
antibody
convergence
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
09
2020
accepted:
16
11
2020
entrez:
1
1
2021
pubmed:
2
1
2021
medline:
16
1
2021
Statut:
epublish
Résumé
Deep sequencing of B cell receptor (BCR) heavy chains from a cohort of 31 COVID-19 patients from the UK reveals a stereotypical naive immune response to SARS-CoV-2 which is consistent across patients. Clonal expansion of the B cell population is also observed and may be the result of memory bystander effects. There was a strong convergent sequence signature across patients, and we identified 1,254 clonotypes convergent between at least four of the COVID-19 patients, but not present in healthy controls or individuals following seasonal influenza vaccination. A subset of the convergent clonotypes were homologous to known SARS and SARS-CoV-2 spike protein neutralizing antibodies. Convergence was also demonstrated across wide geographies by comparison of data sets between patients from UK, USA, and China, further validating the disease association and consistency of the stereotypical immune response even at the sequence level. These convergent clonotypes provide a resource to identify potential therapeutic and prophylactic antibodies and demonstrate the potential of BCR profiling as a tool to help understand patient responses.
Identifiants
pubmed: 33384691
doi: 10.3389/fimmu.2020.605170
pmc: PMC7769841
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Receptors, Antigen, B-Cell
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
605170Informations de copyright
Copyright © 2020 Galson, Schaetzle, Bashford-Rogers, Raybould, Kovaltsuk, Kilpatrick, Minter, Finch, Dias, James, Thomas, Lee, Betley, Cavlan, Leech, Deane, Seoane, Caldas, Pennington, Pfeffer and Osbourn.
Déclaration de conflit d'intérêts
JO, AL, OC, SS, JG, JD, RM, and DF are employees of Alchemab Therapeutics Limited. RB-R is a founder of and consultant to Alchemab Therapeutics Limited. GK is a consultant to Alchemab Therapeutics Limited. CC is a member of the AstraZeneca External Science Panel and has research grants from Roche, Genentech, AstraZeneca, and Servier that are administered by the University of Cambridge. JB was employed by Illumina, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Med. 2020 Sep;26(9):1422-1427
pubmed: 32651581
Nat Immunol. 2015 Jul;16(7):755-65
pubmed: 26006014
Biochem Biophys Res Commun. 2014 Aug 22;451(2):208-14
pubmed: 25073113
Bioinformatics. 2010 Oct 1;26(19):2460-1
pubmed: 20709691
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Bioinformatics. 2014 Jul 1;30(13):1930-2
pubmed: 24618469
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Bioinformatics. 2015 Oct 15;31(20):3356-8
pubmed: 26069265
J Immunol. 2018 Oct 15;201(8):2502-2509
pubmed: 30217829
Microbes Infect. 2020 May - Jun;22(4-5):158
pubmed: 32268188
Bioinformatics. 2021 May 5;37(5):734-735
pubmed: 32805021
Elife. 2016 Aug 02;5:
pubmed: 27481325
J Immunol. 1991 Jun 15;146(12):4385-91
pubmed: 1710250
Bioinformatics. 2012 Dec 1;28(23):3150-2
pubmed: 23060610
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10126-31
pubmed: 10963674
Cell Rep. 2019 May 28;27(9):2690-2708.e10
pubmed: 31141692
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Front Immunol. 2020 Aug 06;11:1734
pubmed: 32849618
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Cell Host Microbe. 2020 Oct 7;28(4):516-525.e5
pubmed: 32941787
Front Immunol. 2020 Dec 15;11:605170
pubmed: 33384691
Genome Med. 2016 Feb 25;8(1):23
pubmed: 26917418
J Infect Dis. 1997 Nov;176(5):1215-24
pubmed: 9359721
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
J Med Virol. 2020 Apr;92(4):401-402
pubmed: 31950516
Clin Infect Dis. 2018 Jan 18;66(3):387-395
pubmed: 29020321
Cell Host Microbe. 2013 Jun 12;13(6):691-700
pubmed: 23768493
Microbes Infect. 2020 Mar;22(2):72-73
pubmed: 32092539
Leukemia. 2003 Dec;17(12):2257-317
pubmed: 14671650
Nat Methods. 2015 May;12(5):380-1
pubmed: 25924071
Nat Commun. 2020 Aug 21;11(1):4198
pubmed: 32826914
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6675-6685
pubmed: 32152119
Immunol Lett. 2020 Sep;225:31-32
pubmed: 32569607
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Immunol. 2008 Mar 1;180(5):3279-88
pubmed: 18292552
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
J Immunol. 2017 Mar 15;198(6):2489-2499
pubmed: 28179494
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W34-40
pubmed: 23671333
ACS Infect Dis. 2016 May 13;2(5):361-76
pubmed: 27627203
Immunol Rev. 2018 Jul;284(1):24-41
pubmed: 29944754
Immunity. 2020 Jul 14;53(1):98-105.e5
pubmed: 32561270
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Immunol Cell Biol. 2015 Nov;93(10):885-95
pubmed: 25976772
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902